Literature DB >> 14510057

Surveillance of adverse events following immunisation: Australia, 2000-2002.

Glenda Lawrence1, Robert Menzies, Margaret Burgess, Peter McIntyre, Nicholas Wood, Ian Boyd, Patrick Purcell, David Isaacs.   

Abstract

The Adverse Drug Reactions Advisory Committee (ADRAC) database collates notifications of adverse events following immunisation (AEFI) from across Australia. The data were analysed for vaccines received between 1 January 2000 and 30 September 2002. Dose-based AEFI reporting rates were calculated using denominator data from the Australian Childhood Immunisation Register and annual national influenza vaccination coverage surveys. The majority of the 2,409 AEFI records analysed described non-serious events, principally injection site reactions; 10.5 per cent (n = 253) described AEFIs with outcomes defined as 'serious'. Ten deaths were recorded but only one, following yellow fever vaccine, was causally related to immunisation. The average annual population-based reporting rate was 4.5 per 100,000 population. Vaccine dose-based AEFI reporting rates were 2.2 per 100,000 doses of influenza vaccine for adults aged 40 years and over and 14.6 per 100,000 doses of all scheduled vaccines for children aged less than 7 years. The most frequently reported type of adverse event was injection site reaction following receipt of an acellular pertussis-containing vaccine, particularly among children in the age groups scheduled to receive their fourth or fifth doses of the vaccine (overall reporting rate 67 per 100,000 doses). The data highlight the safety of vaccines in Australia, and illustrate both the utility of available immunisation coverage data to estimate dose-based AEFI reporting rates and the value of the ADRAC database as a surveillance tool for monitoring AEFIs nationally.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14510057

Source DB:  PubMed          Journal:  Commun Dis Intell Q Rep        ISSN: 1447-4514


  9 in total

Review 1.  Animal models of Q fever (Coxiella burnetii).

Authors:  Kevin R Bewley
Journal:  Comp Med       Date:  2013       Impact factor: 0.982

2.  Reporting of adverse events following immunizations in Ghana - Using disproportionality analysis reporting ratios.

Authors:  Daniel N A Ankrah; Delese M Darko; George Sabblah; Aukje Mantel-Teeuwisse; Hubert M G Leufkens
Journal:  Hum Vaccin Immunother       Date:  2017-11-27       Impact factor: 3.452

3.  STATEMENT FOR TRAVELLERS AND YELLOW FEVER: An Advisory Committee Statement (ACS) Committee to Advise on Tropical Medicine and Travel (CATMAT).

Authors:  This Statement Was Prepared By P Charlebois
Journal:  Can Commun Dis Rep       Date:  2013-03-05

4.  Statement for Travellers and Yellow Fever: Committee to Advise on Tropical Medicine and Travel.

Authors:  P Charlebois
Journal:  Can Commun Dis Rep       Date:  2010-10-02

5.  Incidence of adverse reactions to vaccines in a paediatric population.

Authors:  Pilar Carrasco-Garrido; Carmen Gallardo-Pino; Rodrigo Jiménez-García; Miguel A Tapias; Angel Gil de Miguel
Journal:  Clin Drug Investig       Date:  2004       Impact factor: 2.859

6.  Adverse events following immunization in children: retrospective analysis of spontaneous reports over a decade.

Authors:  Lise Aagaard; Erik Wind Hansen; Ebba Holme Hansen
Journal:  Eur J Clin Pharmacol       Date:  2010-11-16       Impact factor: 3.064

Review 7.  Yellow fever vaccine-associated viscerotropic disease: current perspectives.

Authors:  Roger E Thomas
Journal:  Drug Des Devel Ther       Date:  2016-10-12       Impact factor: 4.162

Review 8.  Challenges in implementing yearly enhanced safety surveillance of influenza vaccination in Europe: lessons learned and future perspectives.

Authors:  Gaël Dos Santos
Journal:  Hum Vaccin Immunother       Date:  2019-05-22       Impact factor: 3.452

9.  Adverse Events of Vaccination against Hepatitis B Virus in Post-Marketing Surveillance from 2005 to 2017 in Guangdong Province, China.

Authors:  Yu Liu; Minyi Zhang; Meiling Yang; Qing Chen
Journal:  Vaccines (Basel)       Date:  2022-07-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.